The Nutraceutical revolution thanks to FM-LipoMatrix® technology.

All Norm Line products are made with the finest raw materials that undergo numerous microbiological tests, both in vivo and in vitro, in terms of both safety and stability, confirming the total absence of pesticides, radioactive waste and chemicals. Production takes place in clean rooms with constantly filtered air to prevent contamination, while temperature and humidity are closely monitored to ensure impeccable quality.

The manufacturing process follows the strictest GMP (Good Manufacturing Practices) standards for food supplements, as established by the World Health Organisation (WHO).

The Norm Line is the result of a completely revolutionary, patented technology that we have named FM-LipoMatrix®.
It is a blend of vegetable oils complexed with specific components, endowed with its own biological activity, capable of improving the effectiveness of lipophilic substances in nutraceutical (and pharmaceutical) formulations.

But that’s not all: FM-LipoMatrix® also allows you to:
– greater water solubility of fat-soluble substances and superior stability of active components;
– optimisation of intestinal absorption and increased bioavailability of ingredients, from 50 to 300%, thanks to an improved delivery system;
– a drastic reduction in side effects due to high dosages.

All active ingredients are first subjected to a fluidisation process: a bed of particles in the product container is transformed into a fluid state by an upward flow of liquid or gas. Once the bed is fully fluidised, the granulation liquid is added: FM-LipoMatrix® technology.

A New Palmitoylethanolamide Form Combined with Antioxidant Molecules to Improve Its Effectivess on Neuronal Aging

Vera Morsanuto *, Rebecca Galla, Claudio Molinari † and Francesca Uberti *,† Laboratory of Physiology, Department of Translational Medicine, University of Piemonte Orientale, Italy
8 May 2020; Accepted: 9 July 2020; Published: 17 July 2020

Palmitoylethanolamide, or PEA, is a long-chain carbon atom molecule that combines with palmitic acid and an ethanolamine group.

It is a molecule with active ingredients that are extremely interesting in cases of chronic or acute pain and inflammation: by not binding directly to endocannabinoid receptors, but acting as a mediator, palmitoylethanolamide participates in the biological response of endogenous cannabinoids and prevents their degradation, thus prolonging their action against pain.

It is no coincidence that Professor Rita Levi Montalcini was among the most eminent scientific sources in Italy to extol the therapeutic value of the PEA molecule: ‘Palmitoylethanolamide is active when taken orally in reducing tissue inflammation and mast cell degranulation in vivo, decreasing the hyperalgesia that accompanies peripheral nerve compression.’*.
PEA exhibits significant anti-inflammatory, analgesic, immunomodulatory and neuroprotective effects, allowing the restoration of glutamatergic transmission homeostasis. Furthermore, PEA’s ability to modulate protective responses during inflammation derives from its belonging to the homeostatic system that controls inflammation, which can counteract the release of inflammatory mediators synthesised de novo by activated mast cells.

Numerous studies and ongoing research highlight the potential of this molecule in the anti-inflammatory and analgesic treatment of clinical conditions with different aetiologies. Without side effects.**

The only drawback, in an otherwise exceptional picture, is its poor bioavailability.
This is where FM-LipoMatrix® comes into play: this is where Artonorm and Peanorm products are created.

* Levi-Montalcini R; Trends Neurosci. 1996 Nov;19(11):514-20. Review

** Review: The Basal Pharmacology of Palmitoylethanolamide
Linda Rankin † and Christopher J. Fowler * Department of Integrative Medical Biology, Umeå University, SE-901 87 Umeå, Sweden;
Published: 26 October 2020

The innovation of hyaluronic acid for joint health

Hyaluronic acid plays a fundamental role in the health and stability of the joint environment: the positive response to the stresses required by movement and natural load variations depends largely on its presence in terms of quantity and quality. In individuals with osteoarthritis, for example, the molecular weight and concentration of hyaluronic acid are reduced, leading to cartilage degeneration.

To address this issue, LeadingMed has created the Reviscon and Vis lines, exploiting the unique viscous and elastic properties of a completely innovative hyaluronic acid, developed through intensive scientific research and sector studies.

– The REVISCON LINE offers a high molecular weight infiltrative therapy based on new generation, highly biocompatible hyaluronic acid.

Reviscon is a highly purified, high molecular weight sodium hyaluronate dissolved in physiological solution.
All synovial joints naturally contain viscoelastic sodium hyaluronate, especially those that bear weight.
In patients with osteoarthritis, for example, the viscoelasticity of the synovial fluid is rather reduced: this causes mechanical stress on the joint, leading to the breakdown of the articular cartilage and thus limiting mobility and causing considerable pain.

Thanks to its range of products, the Reviscon Line relieves pain and contributes to improving overall mobility: in fact, the complex viscosity typical of hyaluronic acid gives it both viscous and elastic properties that are essential for joint health.
The excellent rheological profile of the Reviscon line allows for optimal viscosity at rest (up to 5 times higher than many similar products on the market), and therefore an equally optimal reduction in pain thanks to superior dynamic elasticity when the effort is high.

– Reviscon 20 mg in 2 ml: 3–5 instillations for gradual treatment;
– Reviscon Mono 48 mg in 2.4 ml: a single injection, high performance;
– Reviscon Plus 32 mg in 2 ml: highly effective in 2/3 infiltrations.

The VIS LINE offers an infiltrative therapy based on hyaluronic acid, specialised in reducing symptoms and inflammation, increasing lubrication and viscosity in the joints.

RenehaVis (LMW-HMW dual chamber mix) – 1 to 3 infiltrations per week
RenehaVis consists of a sterile, pre-filled, ready-to-use dual chamber glass syringe containing:

– Chamber 1: Low molecular weight (LMW) sodium hyaluronate 0.7 ml Sterile 2.2% sodium hyaluronate Molecular weight 1 x 106 Da.
– Chamber 2: High molecular weight (HMW) sodium hyaluronate 0.7 ml Sterile 1.0% sodium hyaluronate Molecular weight 2 x 106 Da.

RenehaVis is particularly effective in reducing pain and stiffness in the knee joint in patients with synovial joint degeneration.

The high degree of reliability of RenhaVis is due to its physicochemical properties: the LMW and HMW sodium hyaluronate contained in RenhaVis is a biopolymer composed of disaccharide units of N-acetylglucosamine and glucuronic acid obtained through the biosynthesis of Streptococcus equi, identical to the sodium hyaluronate found naturally in synovial joints, but which may have been altered by degenerative or traumatic changes in the synovial joint.

RenehaVis incorporates synovial sodium hyaluronate that has undergone alterations in molecular weight and concentration.

TendoVis (soft tissue adapted biocompatible Hyaluronic Acid) – 2 injections (one per week)
TendoVis is indicated for periarticular injections for damaged or compromised tendons and ligaments.

– modulates inflammation
– reduces pain
– protects and supports the damaged area
– reduces the risk of recurrence
– reduces recovery time
– facilitates proper realignment of the tendons, resulting in recovery of function.

TendoVis is a sterile glass syringe containing sodium hyaluronate with a pH and osmolarity that are biocompatible with soft tissues. It is therefore suitable for periarticular injection, specifically into the soft tissues surrounding tendons and ligaments.

TendoVis is recommended for patients with rotator cuff tendinopathy, epicondylitis, and ankle sprains: thanks to a sophisticated patented manufacturing process (STABHA patent, Soft Tissue Adapted Biocompatible, Hyaluronic Acid), it allows for prolonged retention time and avoids degradative reactions by the body (thanks to the absence of endotoxins and nucleic acids).

*The I.D.E.H.A. Study Intra-articular Double Molecular Weight Efficacy of Hyaluronic Acid

Authors: Dr Romeo Gatti, Xuming Shen – IDEHA Group
Patients: 1,214 patients in Italy (multicentre study involving over 50 doctors) PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24416477
SAFETY AND EFFECTIVENESS IN PAIN REDUCTION

Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee
Autori: Robert J. Petrella, Joseph Decaria, Michael Petrella
PubMed: http://www.pagepress.org/journals/index.php/rr/article/view/rr.2011.e4/2729

EULAR ROME 2010

LONG-TERM EFFICACY (12-24 MONTHS) AND GREATER EFFICACY COMPARED TO CONVENTIONAL THERAPIES
Efficacy of DualVis (Renehavis) for Knee Osteoarthritis in Indonesia
Authors: Prof. Handono Kalim, Dr. Arif Sumardjono, Dr. Nyimas Fatimah.